Recorded fact · drug.trial_access
drug.trial_access for dulaglutide
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 97a6b255 resolves to.
The record
| Fact id | 97a6b255ab1a6065c9678729 |
|---|---|
| Entity | drug: dulaglutide |
| Field | drug.trial_access |
| Source | clinicaltrials.gov |
| Read on | 2026-11-07T06:34:32.466Z |
| Source version | clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05 |
| Method | api |
| Verification | machine_read |
| Licence | Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. | DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing. |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
This fact carries no verifying quote; its source is the dataset named above.
The value
{
"ingredient": "DULAGLUTIDE",
"recruitingInterventionalCount": 8,
"notYetRecruitingCount": 4,
"byPhase": {
"PHASE3": 2,
"PHASE2": 3,
"PHASE4": 2,
"PHASE2/PHASE3": 1
},
"trials": [
{
"nctId": "NCT07668336",
"briefTitle": "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes",
"phase": [
"PHASE3"
],
"leadSponsor": "Eli Lilly and Company",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2026-11-05",
"startDate": "2026-07-08",
"conditions": [
"Diabetes Mellitus, Type 2"
],
"countries": [
"United States",
"Belgium",
"Brazil",
"India",
"Italy",
"Japan",
"Mexico",
"South Korea",
"Spain",
"Taiwan"
],
"url": "https://clinicaltrials.gov/study/NCT07668336"
},
{
"nctId": "NCT05478707",
"briefTitle": "Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes",
"phase": [
"PHASE2"
],
"leadSponsor": "AdventHealth Translational Research Institute",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2026-10-15",
"startDate": "2023-10-05",
"conditions": [
"Diabetes Mellitus, Type 1",
"Endothelial Dysfunction"
],
"countries": [
"United States"
],
"url": "https://clinicaltrials.gov/study/NCT05478707"
},
{
"nctId": "NCT06739122",
"briefTitle": "A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)",
"phase": [
"PHASE3"
],
"leadSponsor": "Eli Lilly and Company",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2026-08-07",
"startDate": "2025-01-10",
"conditions": [
"Type 2 Diabetes"
],
"countries": [
"United States",
"Argentina",
"Mexico"
],
"url": "https://clinicaltrials.gov/study/NCT06739122"
},
{
"nctId": "NCT04731272",
"briefTitle": "GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance",
"phase": [
"PHASE2"
],
"leadSponsor": "University of Pennsylvania",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2026-05-18",
"startDate": "2021-07-16",
"conditions": [
"Cystic Fibrosis",
"Pancreatic Insufficiency",
"Abnormal Glucose Tolerance"
],
"countries": [
"United States"
],
"url": "https://clinicaltrials.gov/study/NCT04731272"
},
{
"nctId": "NCT06324461",
"briefTitle": "GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery",
"phase": [
"PHASE4"
],
"leadSponsor": "The University of Hong Kong",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2026-05-04",
"startDate": "2024-03-20",
"conditions": [
"Myocardial Injury"
],
"countries": [
"China"
],
"url": "https://clinicaltrials.gov/study/NCT06324461"
},
{
"nctId": "NCT05390892",
"briefTitle": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes",
"phase": [
"PHASE4"
],
"leadSponsor": "Brigham and Women's Hospital",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2026-04-13",
"startDate": "2022-09-26",
"conditions": [
"Type2Diabetes",
"ASCVD"
],
"countries": [
"United States"
],
"url": "https://clinicaltrials.gov/study/NCT05390892"
},
{
"nctId": "NCT07282041",
"briefTitle": "Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis",
"phase": [
"PHASE2",
"PHASE3"
],
"leadSponsor": "National University of Singapore",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2025-12-23",
"startDate": "2025-12-17",
"conditions": [
"Intracranial Atherosclerosis",
"Stroke, Ischemic"
],
"countries": [
"Singapore"
],
"url": "https://clinicaltrials.gov/study/NCT07282041"
},
{
"nctId": "NCT07109700",
"briefTitle": "A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin",
"phase": [
"PHASE2"
],
"leadSponsor": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",
"overallStatus": "RECRUITING",
"lastUpdatePostDate": "2025-08-17",
"startDate": "2025-04-30",
"conditions": [
"Type 2 Diabetes"
],
"countries": [
"China"
],
"url": "https://clinicaltrials.gov/study/NCT07109700"
}
],
"query": {
"intr": "dulaglutide",
"filterOverallStatus": "RECRUITING",
"filterAdvanced": "AREA[StudyType]INTERVENTIONAL",
"sort": "LastUpdatePostDate:desc",
"apiVersion": "2.0.5"
},
"attribution": "ClinicalTrials.gov",
"dataProcessedByRegistry": "2026-11-06T10:00:05",
"modifications": "Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited."
}SHA-256 of the exact stored value: 1769a873f97db5748b0d1a638e5ca9670094a83c7e0c1ad828cb8d92d1d33ccb.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.